Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer-Reference-Cited by-同舟云学术

Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer

Published:2023-12 Issue: Volume:578 Page:216437
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Dogra Samrita,Elayapillai Sugantha Priya^ORCID,Qu Dongfeng,Pitts Kamille,Filatenkov Alexander,Houchen Courtney W.,Berry William L.^ORCID,Moxley Katherine,Hannafon Bethany N.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference48 articles.

1. Cancer statistics, 2022;Siegel;CA A Cancer J. Clin.,2022

2. Impact of recurrence of ovarian cancer on quality of life and outlook for the future;Colombo;Int. J. Gynecol. Cancer,2017

3. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment;van Zyl;Endocr. Relat. Cancer,2018

4. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?;Davis;Gynecol. Oncol.,2014

5. DCLK1-Isoform2 alternative splice variant promotes pancreatic tumor immunosuppressive M2-macrophage polarization;Chandrakesan;Mol. Cancer Therapeut.,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Octreotide modified liposomes that co-deliver paclitaxel and neferine effectively inhibit ovarian cancer metastasis by specifically binding to the SSTR2 receptors;Journal of Drug Delivery Science and Technology;2024-09

2. Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression;Journal of Cancer Research and Clinical Oncology;2024-07-09

3. Deciphering a GPCR-lncrna-miRNA nexus: Identification of an aberrant therapeutic target in ovarian cancer;Cancer Letters;2024-06

4. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine;Cancer Letters;2024-06

5. DCLK1 and its oncogenic functions: A promising therapeutic target for cancers;Life Sciences;2024-01